Summary
The pharmacokinetics of oxiracetam in patients with renal impairment were investigated after administration of a 800 mg single oral dose of oxiracetam. The renal insufficiency was estimated on the basis of the creatinine clearance (CLcr) which ranged from 9 to 95 ml/min among the 20 patients.
In plasma, the terminal elimination half-life (T1/2) ranged from 10.6 to 68.1 h, the highest T1/2 corresponding to the patients with a high degree of renal impairment. In urine, the amounts of oxiracetam excreted during the 48 h postdosing represented 8.3 to 82.6% of the dose. They were lower in patients with a high degree of renal impairment.
The correlations between the total clearance of oxiracetam, the renal clearance, the terminal apparent elimination rate constant in plasma, and CLcr were estimated by linear regression analysis. The correlation coefficients were 0.916, 0.985 and 0.803 respectively. The apparent volume of distribution of the central compartment V(1) and the total volume of distribution at the steady-state V(SS) were not dependent on the degree of renal impairment. The mean values±SD were 25.9±13.0 litres and 48.3±21.5 litres respectively.
Oxiracetam concentrations in plasma of patients were estimated for repeated administration of 800 mg of oxiracetam. The estimations showed that the steady-state concentrations would be obtained after 6–10 days of repeated administration for patients whose CLcr is 9–15 ml/min and 3–5 days for patients with CLcr between 15 and 40 ml/min.
The dosage of oxiracetam in renal insufficient patients was evaluated in order to reach a mean steady-state concentration level of oxiracetam in plasma close to that in patients with normal renal function. For patients with CLcr between 40 and 60 ml/min, the adjusted daily dose would be 50% of the dose given to a patient with normal renal function. For patients with CLcr between 15 and 40 ml/min, the adjusted daily dose would be 25% of the dose given to a patient with normal renal function. For patients whose CLcr was below 40 ml/min, one daily administration in agreement with the dosage reduction, could be given.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Itil T.M., Soldatos C., Bozak M., et al. (1979): CNS effects of ISF-2522. A new nootropic (a phase 1 safety and CNS efficacy study with quantitative pharmaco-EEG and pharmaco-psychology study). Curr. Ther. Res., 26, 525–538.
Itil T.M., Menon G.N., Bozak M., Songar A. (1982): The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double blind controlled study with Piracetam). Drug Dev. Res., 2, 447–461.
Villardita G., Parini J., Grioli S., Quattropani M., Lomeo, Scapagnini U. (1987): Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. J. Neural. Transm. Suppl., 24, 293–298.
Perucca E., Albrici A., Gatti G., Spalluto R., Visconti M., Crema A. (1984): Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers. Eur. J. Drug Metab. Pharmacokinet., 3, 267–274.
Perucca E., Parini J., Albrici A., Visconti M., Ferrero E. (1987): Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly. Eur. J. Drug Metab. Pharmacokinet., 2, 145–148.
Lecaillon J.B., Dubois J.P., Coppens H., Theobald W. Reumond G., Beck H. (1990): Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects. Eur. J. Drug Metab. Pharmacokinet., This issue
Lecaillon J.B., Souppart C., F. Le Duigow, Dubois J.P. (1989): Determination of oxiracetam in plasma and urine by column-switching high performance liquid chromatography. J. Chromatogr., 497, 223–230.
Gerardin A., Wantiez D., Jaouen A. (1983): An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants. J. Pharmacokinet. Biopharm. 11, 401–424.
Ferrero E., (1984): Controlled clinical trial of oxiracetam in the treatment of chronic cerebrovascular insufficiency in the elderly. Curr. Ther. Res. 36, 298–308.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lecaillon, J.B., Dubois, J.P., Coppens, H. et al. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose. Eur. J. Drug Metab. Pharmacokinet. 15, 231–237 (1990). https://doi.org/10.1007/BF03190209
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190209